Martin M et al. |
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. |
2016 |
Ann. Oncol. |
pmid:27052654
|
Coiffier B et al. |
A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. |
2016 |
Br. J. Haematol. |
pmid:27010483
|
Frenel JS et al. |
[Trastuzumab emtansine in the systemic treatment of HER-2-positive breast cancer brain metastases]. |
2016 |
Bull Cancer |
pmid:26992855
|
Lanshoeft C et al. |
Analysis of small molecule antibody-drug conjugate catabolites in rat liver and tumor tissue by liquid extraction surface analysis micro-capillary liquid chromatography/tandem mass spectrometry. |
2016 |
Rapid Commun. Mass Spectrom. |
pmid:26969923
|
Shah MH et al. |
Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors. |
2016 |
Invest New Drugs |
pmid:26961907
|
Dillon RL et al. |
Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance. |
2016 |
J. Immunother. |
pmid:26938945
|
Kashiwaba M et al. |
A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer. |
2016 |
Jpn. J. Clin. Oncol. |
pmid:26917603
|
Squires H et al. |
Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. |
2016 |
Pharmacoeconomics |
pmid:26892972
|
Jerjian TV et al. |
Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy. |
2016 |
Pharmacotherapy |
pmid:26799352
|
Venkatesan P |
Trastuzumab emtansine for HER2-positive breast cancer. |
2016 |
Lancet Oncol. |
pmid:27866859
|
Nonagase Y et al. |
Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1. |
2016 |
Oncotarget |
pmid:27768588
|
Milowsky MI et al. |
Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. |
2016 |
Urol. Oncol. |
pmid:27765518
|
Walles M et al. |
New Insights in Tissue Distribution, Metabolism, and Excretion of [3H]-Labeled Antibody Maytansinoid Conjugates in Female Tumor-Bearing Nude Rats. |
2016 |
Drug Metab. Dispos. |
pmid:27122302
|
Ogitani Y et al. |
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. |
2016 |
Clin. Cancer Res. |
pmid:27026201
|
Baselga J et al. |
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer. |
2016 |
Clin. Cancer Res. |
pmid:26920887
|
Sibaud V et al. |
T-DM1 extravasation: first description. |
2016 |
J Eur Acad Dermatol Venereol |
pmid:25879278
|
Force J et al. |
Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine. |
2016 |
J. Clin. Oncol. |
pmid:24778392
|
Catcott KC et al. |
Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates. |
2016 |
MAbs |
pmid:26752675
|
Yan H et al. |
Ado-Trastuzumab Emtansine Targets Hepatocytes Via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity. |
2016 |
Mol. Cancer Ther. |
pmid:26712117
|
|
Checkpoint Inhibitors Boost Power of Antibody-Drug Conjugate. |
2016 |
Cancer Discov |
pmid:26701087
|
|
T-DM1 Extends Survival in HER2+ Breast Cancer. |
2016 |
Cancer Discov |
pmid:26676162
|
Askoxylakis V et al. |
Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment. |
2016 |
J. Natl. Cancer Inst. |
pmid:26547932
|
Storz U |
Antibody-drug conjugates: Intellectual property considerations. |
2015 |
MAbs |
pmid:26292154
|
Nguyen M et al. |
Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma. |
2015 |
Clin. Cancer Res. |
pmid:26240273
|
Chung YC et al. |
Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1). |
2015 |
PLoS ONE |
pmid:26172389
|
Beerli RR et al. |
Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency. |
2015 |
PLoS ONE |
pmid:26132162
|
van Geel R et al. |
Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody-Drug Conjugates. |
2015 |
Bioconjug. Chem. |
pmid:26061183
|
Miranda Romero P and MarÃn Gil R |
Trastuzumab emtansine in locally advanced or metastatic HER2 positive breast cancer; GENESIS-SEFH drug evaluation report. |
2015 |
Farm Hosp |
pmid:26005893
|
Esteva FJ et al. |
What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience? |
2015 |
Am Soc Clin Oncol Educ Book |
pmid:25993162
|
Hamblett KJ et al. |
AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma. |
2015 |
Mol. Cancer Ther. |
pmid:25931519
|
Ab O et al. |
IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors. |
2015 |
Mol. Cancer Ther. |
pmid:25904506
|
Weiler D et al. |
Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer. |
2015 |
J Thorac Oncol |
pmid:25789838
|
Krop IE et al. |
Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. |
2015 |
J. Clin. Oncol. |
pmid:25713436
|
Marcoux J et al. |
Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate. |
2015 |
Protein Sci. |
pmid:25694334
|
Goldmacher VS et al. |
High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction. |
2015 |
PLoS ONE |
pmid:25671541
|
Müller P et al. |
Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. |
2015 |
Sci Transl Med |
pmid:26606967
|
Eisenstein M |
Medicine: Eyes on the target. |
2015 |
Nature |
pmid:26580159
|
Widdison WC et al. |
Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolites in Cancer Cells and Induce High Levels of Bystander Killing. |
2015 |
Bioconjug. Chem. |
pmid:26355774
|
Cosmai L et al. |
Renal toxicity of anticancer agents targeting HER2 and EGFR. |
2015 |
J. Nephrol. |
pmid:26341657
|
Fishkin N |
Maytansinoid-BODIPY Conjugates: Application to Microscale Determination of Drug Extinction Coefficients and for Quantification of Maytansinoid Analytes. |
2015 |
Mol. Pharm. |
pmid:25738231
|
Goldmacher VS et al. |
Statistics of the distribution of the abundance of molecules with various drug loads in maytansinoid antibody-drug conjugates. |
2015 |
Mol. Pharm. |
pmid:25635630
|
Ahmed S et al. |
HER2-directed therapy: current treatment options for HER2-positive breast cancer. |
2015 |
Breast Cancer |
pmid:25634227
|
Foglietta J et al. |
Letter to the editor concerning 'Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA'. |
2015 |
Ann. Oncol. |
pmid:25632067
|
Wiggins B et al. |
Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates. |
2015 |
J Pharm Sci |
pmid:25631158
|
Lai KC et al. |
Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay. |
2015 |
Pharm. Res. |
pmid:25630819
|
Li T et al. |
Improvement of ansamitocin P-3 production by Actinosynnema mirum with fructose as the sole carbon source. |
2015 |
Appl. Biochem. Biotechnol. |
pmid:25564203
|
Carneiro BA et al. |
Emerging therapeutic targets in bladder cancer. |
2015 |
Cancer Treat. Rev. |
pmid:25498841
|
Mang Y et al. |
Efficient elimination of CD103-expressing cells by anti-CD103 antibody drug conjugates in immunocompetent mice. |
2015 |
Int. Immunopharmacol. |
pmid:25467246
|
Kalsi R et al. |
Brain metastasis and response to ado-trastuzumab emtansine: a case report and literature review. |
2015 |
Clin. Breast Cancer |
pmid:25454740
|
Sibaud V et al. |
T-DM1-related telangiectasias: a potential role in secondary bleeding events. |
2015 |
Ann. Oncol. |
pmid:25403586
|